Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Merck Serono/Compugen, Lilly/PrimeraDx, Biogen Idec/Isis

Executive Summary

With the Supreme Court upholding the Patient Protection and Affordable Care Act, the pharma sector can look forward to a projected 8.8% increase in prescription drug spending in 2014.

You may also be interested in...



The Unlikely Renaissance Of Gene Therapy

After a decade of doubts, fears, and scares, advances in gene therapy have brought one drug close to approval, and a few venture-backed start-ups are gaining momentum. Is it enough to persuade more VCs to jump in?

Merck/AstraZeneca Stay Tied To Each Other For Another Two Years

Merck and AstraZeneca continue a 30-year partnership after coming to terms that could benefit both companies.

Merck Serono Ventures, Compugen Team Up On Drug Toxicity Biomarker Start-Up

Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel